Atrium Therapeutics Begins Operations With 2 Precision Cardiology Candidates

MT Newswires Live

02/27

Atrium Therapeutics (RNA) said Friday it has started operations as an independent, publicly traded company with lead precision cardiology candidates ATR 1072 and ATR 1086.

The company also said it has about $270 million in cash and cash equivalents, and two undisclosed research targets.

Atrium said ATR 1072 is currently in preclinical studies for PRKAG2 syndrome, with an investigational new drug filing expected in H2, while ATR 1086 is expected to enter preclinical studies this year for phospholamban cardiomyopathy, with an IND filing targeted in 2027.

Atrium was spun out of Avidity Biosciences as part of Avidity's acquisition by Novartis (NVS). The acquisition was completed Friday, Novartis said.

Shares of Atrium Therapeutics were down 2.7% in recent Friday trading.

Price: 13.79, Change: -0.99, Percent Change: -6.71

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2614850908"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614850908\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614850908?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 23:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614850908","market":"sh","top_or_hot":-1,"title":"Atrium Therapeutics Begins Operations With 2 Precision Cardiology Candidates","media":"MT Newswires Live","content":"<html><body><p> Atrium <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (RNA) said Friday it has started operations as an independent, publicly traded company with lead precision cardiology candidates ATR 1072 and ATR 1086.</p><p>The company also said it has about $270 million in cash and cash equivalents, and two undisclosed research targets.</p><p>Atrium said ATR 1072 is currently in preclinical studies for PRKAG2 syndrome, with an investigational new drug filing expected in H2, while ATR 1086 is expected to enter preclinical studies this year for phospholamban cardiomyopathy, with an IND filing targeted in 2027.</p><p>Atrium was spun out of <a href=\"https://laohu8.com/S/RNA\">Avidity Biosciences</a> as part of Avidity's acquisition by Novartis (NVS). The acquisition was completed Friday, Novartis said.</p><p>Shares of Atrium Therapeutics were down 2.7% in recent Friday trading.</p><p>Price: 13.79, Change: -0.99, Percent Change: -6.71</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Atrium Therapeutics Begins Operations With 2 Precision Cardiology Candidates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAtrium Therapeutics Begins Operations With 2 Precision Cardiology Candidates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-27 23:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Atrium <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (RNA) said Friday it has started operations as an independent, publicly traded company with lead precision cardiology candidates ATR 1072 and ATR 1086.</p><p>The company also said it has about $270 million in cash and cash equivalents, and two undisclosed research targets.</p><p>Atrium said ATR 1072 is currently in preclinical studies for PRKAG2 syndrome, with an investigational new drug filing expected in H2, while ATR 1086 is expected to enter preclinical studies this year for phospholamban cardiomyopathy, with an IND filing targeted in 2027.</p><p>Atrium was spun out of <a href=\"https://laohu8.com/S/RNA\">Avidity Biosciences</a> as part of Avidity's acquisition by Novartis (NVS). The acquisition was completed Friday, Novartis said.</p><p>Shares of Atrium Therapeutics were down 2.7% in recent Friday trading.</p><p>Price: 13.79, Change: -0.99, Percent Change: -6.71</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2614850908","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614850908","pubTimestamp":1772206324,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Atrium Therapeutics  said Friday it has started operations as an independent, publicly traded company with lead precision cardiology candidates ATR 1072 and ATR 1086.The company also said it has about $270 million in cash and cash equivalents, and two undisclosed research targets.Atrium said ATR 1072 is currently in preclinical studies for PRKAG2 syndrome, with an investigational new drug filing expected in H2, while ATR 1086 is expected to enter preclinical studies this year for phospholamban cardiomyopathy, with an IND filing targeted in 2027.Atrium was spun out of Avidity Biosciences as part of Avidity's acquisition by Novartis . The acquisition was completed Friday, Novartis said.Shares of Atrium Therapeutics were down 2.7% in recent Friday trading.Price: 13.79, Change: -0.99, Percent Change: -6.71","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LENZ":"Therapeutics","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4007":"制药","RNA":"Atrium Therapeutics","BK4539":"次新股","BK4532":"文艺复兴科技持仓","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","BK4139":"生物科技","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4585":"ETF&股票定投概念","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","NVS":"诺华","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4505":"高瓴资本持仓","BK4578":"CAR-T","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC"},"translate_title":"Atrium Therapeutics开始运营2款精准心脏病学候选药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNA":1,"NVS":1,"LENZ":1.5},"content_text":"Atrium Therapeutics (RNA) said Friday it has started operations as an independent, publicly traded company with lead precision cardiology candidates ATR 1072 and ATR 1086.The company also said it has about $270 million in cash and cash equivalents, and two undisclosed research targets.Atrium said ATR 1072 is currently in preclinical studies for PRKAG2 syndrome, with an investigational new drug filing expected in H2, while ATR 1086 is expected to enter preclinical studies this year for phospholamban cardiomyopathy, with an IND filing targeted in 2027.Atrium was spun out of Avidity Biosciences as part of Avidity's acquisition by Novartis (NVS). The acquisition was completed Friday, Novartis said.Shares of Atrium Therapeutics were down 2.7% in recent Friday trading.Price: 13.79, Change: -0.99, Percent Change: -6.71","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}